Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival.

Background: Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event following immune checkpoint inhibitor (ICI) therapy for cancer. IMC has been associated with improved overall survival (OS) and progression-free survival (PFS), but data are limited to a single site and predominantly for melanoma patients.

Aim: To determine the association of IMC with OS and PFS and identify clinical predictors of IMC.